Prothena Corp. Plc - Ordinary Shares (MM) News - PRTAV

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors DUBLIN, Ireland, May 20, 2021 (GLOBE NEWSWIRE) -- Prothena...

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update Net cash used in operating...

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab ...

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab in Early...

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, May 07, 2021 (GLOBE NEWSWIRE) -- Prothena...

Prothena to Report First Quarter 2021 Financial Results on May 11th

Prothena to Report First Quarter 2021 Financial Results on May 11th DUBLIN, Ireland, May 04, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation...

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021 Slowing of neuropathy progression for all 7 evaluable...

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021 DUBLIN, Ireland, April 15, 2021...

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, April 07, 2021 (GLOBE NEWSWIRE) -- Prothena...

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer Dr. Garren’s extensive expertise and successful track...

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares DUBLIN, Ireland, March 24, 2021 (GLOBE NEWSWIRE) -- Prothena...

Prothena Announces Proposed Offering of Ordinary Shares

Prothena Announces Proposed Offering of Ordinary Shares DUBLIN, Ireland, March 23, 2021 (GLOBE NEWSWIRE) -- Prothena Corporation plc...

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021 Superior profile of novel anti-tau antibody PRX005...

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presenta...

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presentations at AD/PD...

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update Net cash used in...

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DUBLIN, Ireland, Feb. 05, 2021 (GLOBE NEWSWIRE) -- Prothena...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PRTAV News

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab ...

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Report First Quarter 2021 Financial Results on May 11th

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

Prothena Announces Proposed Offering of Ordinary Shares

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presenta...

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRTAV Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV) News

Prothena Corp. Plc - Ordinary Shares (MM) (PRTAV)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

PRTAV News

Prothena Announces Appointment of Sanjiv Patel, MBBS, to its Board of Directors

Prothena Reports First Quarter 2021 Financial Results and Provides Updated Financial Guidance and R&D Update

Prothena Announces Achievement of $60 Million Milestone From Roche for First Patient Dosed in Phase 2b Study of Prasinezumab ...

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Prothena to Report First Quarter 2021 Financial Results on May 11th

Prothena Presents Phase 1 Study Results of PRX004 in Oral Presentation at AAN 2021

Prothena Announces PRX004 Phase 1 Study Results Selected for Emerging Science Oral Presentation at AAN 2021

Prothena Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Prothena Announces Appointment of Hideki Garren, MD, PhD, as Chief Medical Officer

Prothena Announces Pricing of Public Offering of 3,500,000 Ordinary Shares

Prothena Announces Proposed Offering of Ordinary Shares

Prothena to Hold Investor Webcast to Review Three Oral Presentations from AD/PD 2021

Prothena Announces Promising New Preclinical and Clinical Data from its Neurodegenerative Programs Selected for Oral Presenta...

Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update

Prothena Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PRTAV Discussion

Your Recent History